GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-small Cell Lung Cancer (nsclc)
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1)Patients with Stage III/IV NSCLC on treatment with anti-PD-1/PD-L1 (ICI)+/ -chemotherapy. 2) Patients who have measurable disease including a lesion that is amenable to injection. 3) Patients who are able and willing to undergo a pre-treatment and on-treatment biopsy.

You may not be eligible for this study if the following are true:

  • 1) Patients with a history of severe hypersensitivity reaction to ICI. 2) Patients who require ongoing therapy with systemic immunosuppressive drugs including systemic corticosteroids. 3) Patients with a history of active autoimmune disease requiring treatment in the past 2 years.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.